Alzheimer’s drugs Market - Global Industry Analysis

Alzheimer’s drugs Market By Drug class (Donepezil, Galantamine, Rivastigmine, Memantine, Others), By Distribution channel (Hospital Pharmacy, Retail Pharmacy, Online Stores, Others), and By Region – Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028

Published Date: 10-May-2022 Category: Pharmaceutical Report Format : PDF Pages: 188 Report Code: ZMR-2513 Status : Published

The global Alzheimer’s drugs market was worth around USD 6,429.5 billion in 2021 and is estimated to grow to about USD 9276.3 billion by 2028, with a compound annual growth rate (CAGR) of approximately 6.3 percent over the forecast period.

Description

Industry Prospective:

The global Alzheimer’s drugs market was worth around USD 6,429.5 billion in 2021 and is estimated to grow to about USD 9276.3 billion by 2028, with a compound annual growth rate (CAGR) of approximately 6.3 percent over the forecast period. The report analyzes the Alzheimer’s drugs market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the Alzheimer’s drugs market.

Alzheimer’s drugs Market: Overview

Alzheimer’s drugs are used in the treatment of Alzheimer which is a rare disease that is increasing in incidence over the past few years. This neurodegenerative disorder causes brain cells to die and this results in mostly loss of memory and a decline in functionality of the brain and other organs of the body.

The increasing prevalence of Alzheimer’s is expected to be the major factor driving Alzheimer’s drugs market growth. Apart from this increasing awareness regarding Alzheimer’s and rising research and development for the treatment of the disease are expected to influence Alzheimer’s drugs market potential over the forecast period.

However, discontinuation of clinical trials for Alzheimer’s from major pharmaceutical and healthcare companies is expected to have a hindering effect on the Alzheimer’s drugs market growth.

COVID-19 Impact:

The emergence of the COVID-19 pandemic led to a major negative impact on the Alzheimer’s drugs market as diagnostic and therapeutic procedures around the world were impacted due to the decline in visits to hospitals and diagnostic centers because of lockdown restrictions imposed by various governments to curb the spread of coronavirus infections across nations. The shift of focus from other health conditions to coronavirus also had an adverse impact on the Alzheimer’s drugs market growth.

With vaccinations picking up pace and a decline in COVID cases across the world, the Alzheimer’s drugs market is anticipated to make a comeback in the post-pandemic era at a steady pace through 2028. Resumption of normal world activity and a shift of focus on other health conditions apart from COVID will drive Alzheimer’s drugs market growth at a steady pace through 2028.

Global Alzheimer’s Drugs Market

Alzheimer’s drugs Market: Growth Drivers

Increasing Research and Development Activity

Advancements in pharmaceutical and healthcare industries have spawned a new wave of research and development activities across the world and this trend is the same for the Alzheimer’s drugs market as well. As the incidence of Alzheimer’s is on the rise pharmaceutical companies are focusing on the development of novel treatments to maximize their revenue potential as instances of these diseases increases on a global level.

Alzheimer’s drugs Market: Restraints

Discontinuation of Clinical Trials to Hamper Alzheimer’s drugs Market growth

Alzheimer’s has been around for quite a while now but there has been no discovery of a definite treatment for the disease and this has led to skepticism around investments in research and development for the same. This skepticism has led to the discontinuation of clinical trials for the development of Alzheimer’s drugs and hence has had a hindering effect on the global Alzheimer’s drugs market growth. This trend is expected to be prevalent over the forecast period.

Global Alzheimer’s drugs Market: Segmentation

The global Alzheimer’s drugs market is segregated based on drug class, distribution channel, and region.

By Distribution channel, the Alzheimer’s drugs market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Stores, and Others. The hospital pharmacies segment is projected to account for a dominant market share in the global Alzheimer’s drugs market landscape and this trend is expected to be prominent over the forecast period as well.  

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Recent Developments

  • In December 2018 – Eli Lilly and Company a leading name in the pharmaceutical industry announced a collaboration with AC Immune to develop a new treatment for Alzheimer’s which will be done by utilizing AC Immune’s Morphomer platform.

Regional Landscape

North America region leads the global Alzheimer’s drugs market in terms of revenue and volume share and is projected to follow the same trend over the forecast period. The presence of key pharmaceutical and healthcare companies, rising research and development activity in the region, and increasing investments in the development of treatment for Alzheimer’s are some of the major factors that drive the Alzheimer’s drugs market potential in this region. The increasing aging population in North America is also expected to boost the incidence of Alzheimer’s and this is expected to propel the demand for Alzheimer’s drugs over the forecast period. The United States is anticipated to be the most notable market in this region through 2028. The rising prevalence of Alzheimer’s disease and increasing launches of new Alzheimer’s drugs are expected to be prominent trends driving market growth in the U.S.

Competitive Landscape

Some of the main competitors dominating the global Alzheimer’s drugs market include – Abbvie Inc., AstraZeneca PLC, Biogen Inc., Daiichi Sankyo Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc and Teva Pharmaceutical Industries Limited

Global Alzheimer’s drugs market is segmented as follows:

By Drug class

  • Donepezil
  • Galantamine
  • Rivastigmine
  • Memantine
  • Others

By Distribution channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Stores
  • Others

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market research methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Alzheimer’s drugs Market, (2022 - 2028) (USD Billion)
    • 2.2 Global Alzheimer’s drugs Market : snapshot
  • Chapter 3. Global Alzheimer’s drugs Market - Industry Analysis
    • 3.1 Alzheimer’s drugs Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Increasing Research and Development Activity
    • 3.3 Market Restraints
      • 3.3.1. Discontinuation of Clinical Trials to Hamper Alzheimer’s drugs Market growth
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market attractiveness analysis By Drug class
      • 3.7.2 Market attractiveness analysis By Distribution channel
  • Chapter 4. Global Alzheimer’s drugs Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Alzheimer’s drugs Market: company market share, 2021
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Alzheimer’s drugs Market - Drug class Analysis
    • 5.1 Global Alzheimer’s drugs Market overview: By Drug class
      • 5.1.1 Global Alzheimer’s drugs Market share, By Drug class, 2021 and 2028
    • 5.2 Donepezil
      • 5.2.1 Global Alzheimer’s drugs Market by Donepezil, 2022 - 2028 (USD Billion)
    • 5.3 Galantamine
      • 5.3.1 Global Alzheimer’s drugs Market by Galantamine, 2022 - 2028 (USD Billion)
    • 5.4 Rivastigmine
      • 5.4.1 Global Alzheimer’s drugs Market by Rivastigmine, 2022 - 2028 (USD Billion)
    • 5.5 Memantine
      • 5.5.1 Global Alzheimer’s drugs Market by Memantine, 2022 - 2028 (USD Billion)
    • 5.6 Others
      • 5.6.1 Global Alzheimer’s drugs Market by Others, 2022 - 2028 (USD Billion)
  • Chapter 6. Global Alzheimer’s drugs Market - Distribution channel Analysis
    • 6.1 Global Alzheimer’s drugs Market overview: By Distribution channel
      • 6.1.1 Global Alzheimer’s drugs Market share, By Distribution channel, 2021 and 2028
    • 6.2 Hospital Pharmacy
      • 6.2.1 Global Alzheimer’s drugs Market by Hospital Pharmacy, 2022 - 2028 (USD Billion)
    • 6.3 Retail Pharmacy
      • 6.3.1 Global Alzheimer’s drugs Market by Retail Pharmacy, 2022 - 2028 (USD Billion)
    • 6.4 Online Stores
      • 6.4.1 Global Alzheimer’s drugs Market by Online Stores, 2022 - 2028 (USD Billion)
    • 6.5 Others
      • 6.5.1 Global Alzheimer’s drugs Market by Others, 2022 - 2028 (USD Billion)
  • Chapter 7. Alzheimer’s drugs Market - Regional Analysis
    • 7.1 Global Alzheimer’s drugs Market Regional Overview
    • 7.2 Global Alzheimer’s drugs Market Share, by Region, 2021 & 2028 (USD Billion)
    • 7.3. North America
      • 7.3.1 North America Alzheimer’s drugs Market, 2022 - 2028 (USD Billion)
        • 7.3.1.1 North America Alzheimer’s drugs Market, by Country, 2022 - 2028 (USD Billion)
    • 7.4 North America Alzheimer’s drugs Market, by Drug class, 2022 - 2028
      • 7.4.1 North America Alzheimer’s drugs Market, by Drug class, 2022 - 2028 (USD Billion)
    • 7.5 North America Alzheimer’s drugs Market, by Distribution channel, 2022 - 2028
      • 7.5.1 North America Alzheimer’s drugs Market, by Distribution channel, 2022 - 2028 (USD Billion)
    • 7.4. Europe
      • 7.4.2 Europe Alzheimer’s drugs Market, 2022 - 2028 (USD Billion)
        • 7.4.2.1 Europe Alzheimer’s drugs Market, by Country, 2022 - 2028 (USD Billion)
    • 7.4 Europe Alzheimer’s drugs Market, by Drug class, 2022 - 2028
      • 7.4.1 Europe Alzheimer’s drugs Market, by Drug class, 2022 - 2028 (USD Billion)
    • 7.5 Europe Alzheimer’s drugs Market, by Distribution channel, 2022 - 2028
      • 7.5.1 Europe Alzheimer’s drugs Market, by Distribution channel, 2022 - 2028 (USD Billion)
    • 7.5. Asia Pacific
      • 7.5.3 Asia Pacific Alzheimer’s drugs Market, 2022 - 2028 (USD Billion)
        • 7.5.3.1 Asia Pacific Alzheimer’s drugs Market, by Country, 2022 - 2028 (USD Billion)
    • 7.4 Asia Pacific Alzheimer’s drugs Market, by Drug class, 2022 - 2028
      • 7.4.1 Asia Pacific Alzheimer’s drugs Market, by Drug class, 2022 - 2028 (USD Billion)
    • 7.5 Asia Pacific Alzheimer’s drugs Market, by Distribution channel, 2022 - 2028
      • 7.5.1 Asia Pacific Alzheimer’s drugs Market, by Distribution channel, 2022 - 2028 (USD Billion)
    • 7.6. Latin America
      • 7.6.4 Latin America Alzheimer’s drugs Market, 2022 - 2028 (USD Billion)
        • 7.6.4.1 Latin America Alzheimer’s drugs Market, by Country, 2022 - 2028 (USD Billion)
    • 7.4 Latin America Alzheimer’s drugs Market, by Drug class, 2022 - 2028
      • 7.4.1 Latin America Alzheimer’s drugs Market, by Drug class, 2022 - 2028 (USD Billion)
    • 7.5 Latin America Alzheimer’s drugs Market, by Distribution channel, 2022 - 2028
      • 7.5.1 Latin America Alzheimer’s drugs Market, by Distribution channel, 2022 - 2028 (USD Billion)
    • 7.7. The Middle-East and Africa
      • 7.7.5 The Middle-East and Africa Alzheimer’s drugs Market, 2022 - 2028 (USD Billion)
        • 7.7.5.1 The Middle-East and Africa Alzheimer’s drugs Market, by Country, 2022 - 2028 (USD Billion)
    • 7.4 The Middle-East and Africa Alzheimer’s drugs Market, by Drug class, 2022 - 2028
      • 7.4.1 The Middle-East and Africa Alzheimer’s drugs Market, by Drug class, 2022 - 2028 (USD Billion)
    • 7.5 The Middle-East and Africa Alzheimer’s drugs Market, by Distribution channel, 2022 - 2028
      • 7.5.1 The Middle-East and Africa Alzheimer’s drugs Market, by Distribution channel, 2022 - 2028 (USD Billion)
  • Chapter 8. Company Profiles
    • 8.1 Abbvie Inc.
      • 8.1.1 Overview
      • 8.1.2 Financials
      • 8.1.3 Product Portfolio
      • 8.1.4 Business Strategy
      • 8.1.5 Recent Developments
    • 8.2 AstraZeneca PLC
      • 8.2.1 Overview
      • 8.2.2 Financials
      • 8.2.3 Product Portfolio
      • 8.2.4 Business Strategy
      • 8.2.5 Recent Developments
    • 8.3 Biogen Inc.
      • 8.3.1 Overview
      • 8.3.2 Financials
      • 8.3.3 Product Portfolio
      • 8.3.4 Business Strategy
      • 8.3.5 Recent Developments
    • 8.4 Daiichi Sankyo Company Limited
      • 8.4.1 Overview
      • 8.4.2 Financials
      • 8.4.3 Product Portfolio
      • 8.4.4 Business Strategy
      • 8.4.5 Recent Developments
    • 8.5 Daiichi Sankyo Company Limited
      • 8.5.1 Overview
      • 8.5.2 Financials
      • 8.5.3 Product Portfolio
      • 8.5.4 Business Strategy
      • 8.5.5 Recent Developments
    • 8.6 Eisai Co. Ltd.
      • 8.6.1 Overview
      • 8.6.2 Financials
      • 8.6.3 Product Portfolio
      • 8.6.4 Business Strategy
      • 8.6.5 Recent Developments
    • 8.7 Eli Lilly and Company
      • 8.7.1 Overview
      • 8.7.2 Financials
      • 8.7.3 Product Portfolio
      • 8.7.4 Business Strategy
      • 8.7.5 Recent Developments
    • 8.8 H. Lundbeck A/S
      • 8.8.1 Overview
      • 8.8.2 Financials
      • 8.8.3 Product Portfolio
      • 8.8.4 Business Strategy
      • 8.8.5 Recent Developments
    • 8.9 F. Hoffmann-La Roche AG
      • 8.9.1 Overview
      • 8.9.2 Financials
      • 8.9.3 Product Portfolio
      • 8.9.4 Business Strategy
      • 8.9.5 Recent Developments
    • 8.10 Merck & Co. Inc.
      • 8.10.1 Overview
      • 8.10.2 Financials
      • 8.10.3 Product Portfolio
      • 8.10.4 Business Strategy
      • 8.10.5 Recent Developments
    • 8.11 Novartis AG
      • 8.11.1 Overview
      • 8.11.2 Financials
      • 8.11.3 Product Portfolio
      • 8.11.4 Business Strategy
      • 8.11.5 Recent Developments
    • 8.12 Ono Pharmaceutical Co. Ltd.
      • 8.12.1 Overview
      • 8.12.2 Financials
      • 8.12.3 Product Portfolio
      • 8.12.4 Business Strategy
      • 8.12.5 Recent Developments
    • 8.13 Pfizer Inc
      • 8.13.1 Overview
      • 8.13.2 Financials
      • 8.13.3 Product Portfolio
      • 8.13.4 Business Strategy
      • 8.13.5 Recent Developments
    • 8.14 Teva Pharmaceutical Industries Limited
      • 8.14.1 Overview
      • 8.14.2 Financials
      • 8.14.3 Product Portfolio
      • 8.14.4 Business Strategy
      • 8.14.5 Recent Developments

Table Of Figures

  • 1. Market research Type
  • 2. Market research methodology
  • 3. Global Alzheimer’s drugs Market, 2022 - 2028 (USD Billion)
  • 4. Porter’s Five Forces Analysis
  • 5. Global Alzheimer’s drugs Market attractiveness, By Drug class
  • 6. Global Alzheimer’s drugs Market attractiveness, By Distribution channel
  • 7. Global Alzheimer’s drugs Market share by Drug class, 2022 and 2028 (USD Billion)
  • 8. Global Alzheimer’s drugs Market by Donepezil, 2022 - 2028 (USD Billion)
  • 9. Global Alzheimer’s drugs Market by Galantamine, 2022 - 2028 (USD Billion)
  • 10. Global Alzheimer’s drugs Market by Rivastigmine, 2022 - 2028 (USD Billion)
  • 11. Global Alzheimer’s drugs Market by Memantine, 2022 - 2028 (USD Billion)
  • 12. Global Alzheimer’s drugs Market by Others, 2022 - 2028 (USD Billion)
  • 13. Global Alzheimer’s drugs Market share by Distribution channel, 2022 and 2028 (USD Billion)
  • 14. Global Alzheimer’s drugs Market by Hospital Pharmacy, 2022 - 2028 (USD Billion)
  • 15. Global Alzheimer’s drugs Market by Retail Pharmacy, 2022 - 2028 (USD Billion)
  • 16. Global Alzheimer’s drugs Market by Online Stores, 2022 - 2028 (USD Billion)
  • 17. Global Alzheimer’s drugs Market by Others, 2022 - 2028 (USD Billion)
  • 18. Global Alzheimer’s drugs Market share, by Region, 2022 and 2028
  • 19. North America Alzheimer’s drugs Market, 2022 - 2028 (USD Billion)
  • 20. Europe Alzheimer’s drugs Market, 2022 - 2028 (USD Billion)
  • 21. Asia Pacific Alzheimer’s drugs Market, 2022 - 2028 (USD Billion)
  • 22. Latin America Alzheimer’s drugs Market, 2022 - 2028 (USD Billion)
  • 23. The Middle-East and Africa Alzheimer’s drugs Market, 2022 - 2028 (USD Billion)

Table Of Tables

  • 1. Global Alzheimer’s drugs Market: Snapshot
  • 2. Drivers of the Alzheimer’s drugs Market: impact analysis
  • 3. North America Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 4. North America Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 5. U.S. Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 6. U.S. Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 7. Canada Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 8. Canada Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 9. Europe Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 10. Europe Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 11. Germany Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 12. Germany Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 13. France Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 14. France Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 15. U.K. Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 16. U.K. Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 17. Italy Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 18. Italy Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 19. Spain Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 20. Spain Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 21. Rest of Europe Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 22. Rest of Europe Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 23. Asia Pacific Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 24. Asia Pacific Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 25. China Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 26. China Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 27. Japan Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 28. Japan Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 29. India Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 30. India Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 31. South Korea Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 32. South Korea Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 33. South-East Asia Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 34. South-East Asia Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 35. Rest of Asia Pacific Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 36. Rest of Asia Pacific Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 37. Latin America Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 38. Latin America Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 39. Brazil Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 40. Brazil Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 41. Mexico Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 42. Mexico Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 43. Rest of Latin America Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 44. Rest of Latin America Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 45. The Middle-East and Africa Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 46. The Middle-East and Africa Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 47. GCC Countries Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 48. GCC Countries Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 49. South Africa Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 50. South Africa Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)
  • 51. Rest of Middle-East Africa Alzheimer’s drugs Market revenue, By Drug class, 2022 - 2028 (USD Billion)
  • 52. Rest of Middle-East Africa Alzheimer’s drugs Market revenue, By Distribution channel, 2022 - 2028 (USD Billion)

Methodology

Free Analysis

Alzheimer's disease is a type of dementia which includes a broad group of brain diseases, such as problems with memory, thinking, and behavior for long term. Causes of Alzheimer’s diseases are still unknown. Alzheimer’s symptoms usually grow slowly and get worse over time. It becomes severe, enough to obstruct a patient’s daily activity. Many researchers consider increasing level of a protein called amyloid in the brain as one of the major causes of Alzheimer disease. It may cause the death of the nerve cells. Major risk factor for Alzheimer disease is growing age wherein people aged 65 and older majorly tend to suffer from Alzheimer disease. Additionally, there are also some genetic and some other causes of Alzheimer diseases. At this moment there is no treatment which can stop the growth of the Alzheimer’s disease. But scientist and researchers are working continuously on it. 

According to Center of Disease Control and Prevention (CDC), in 2017 near about 5.5 million Americans were suffering from Alzheimer’s diseases. Alzheimer is considered as the fifth leading cause of death for all adults. The market is mainly driven by the growing occurrence of diseases in developed countries specifically in the Western region. Also, the prevalence of some neurodegenerative diseases such as dementia has grown in the U.S. In addition, growing occurrence of diseases, firm government encouragement for Alzheimer’s drug development and growing alertness about the treatment of Alzheimer ’s disease is resulting into increased demand for Alzheimer’s drugs market. Furthermore, growing support for psychological care infrastructure from governments in several developing Asia Pacific countries is likely to drive the Alzheimer's drugs market. However, high prices of the advance drugs may create restraints in underdeveloped countries. Awareness about Alzheimer’s disease in developing regions remains restricted that has resulted in unbalanced healthcare systems and obstructive research infrastructure. In Asia Pacific region, growing encouragement for mental care by governments is anticipated to drive the Alzheimer's drugs market in the near future.

Global Alzheimer Drugs Market

The Alzheimer’s drugs market is classified based on drug class, distribution channel, and region. On the basis of drug class, the market is divided into, memantine, cholinergic, and combined drug. Memantine drug-dominated the global Alzheimer’s drugs market in 2017 due to the large range expiry of patents of key products and a limited number of medicines to treat Alzheimer’s disease. Memantine drug segment is anticipated to lead the market in the forecast period. Owing to the inadequate availability of the productive drug classes all over the globe, the cholinergic segment is also estimated to contribute primarily to the overall market share of the global market for Alzheimer’s drug market. And it is predicted to expand at a moderate growth rate over the forecast period. On the basis of distribution channel, the market is divided into hospital pharmacy, retail pharmacy, and online sales.
 
Demand for Alzheimer’s drug is growing worldwide, with North America and Europe contributing majorly to the Alzheimer’s drug market. North America dominated the Alzheimer’s drug market in 2017 due to the growing occurrence of disease in this region. This region will continue to remain the principal segment for Alzheimer's drugs market in the future. 

The Asia Pacific is the highest growing market and is expected to remain the same in the coming future. Due to growing awareness of Alzheimer’s treatment in the Asia Pacific region, this region is a key contributor to the global Alzheimer's drugs market in the coming years. Latin America is another key geographical market and is likely to have a moderate growth in the future due to developing healthcare infrastructure and rising awareness. The Middle East and Africa region are anticipated to witness significant growth within the forecast period. 
Some of the key players in Alzheimer’s drugs market include Ono Pharmaceutical, Johnson & Johnson, Daiichi Sankyo Company Limited, H Lundbeck A/S, and Eisai Co. Ltd., among others.

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

Increasing prevalence of Alzheimer’s and rising research and development in the pharmaceutical sector are major trends that guide Alzheimer’s drugs market growth.

According to the Market Research report, the global Alzheimer’s drugs market was worth about US$ 6,429.5 billion in 2021 and is predicted to grow to around US$ 9276.3 billion by 2028, with a compound annual growth rate (CAGR) of around 6.3 percent.

North America region leads the global Alzheimer’s drugs market in terms of revenue and volume share and is projected to follow the same trend over the forecast period. The presence of key pharmaceutical and healthcare companies, rising research and development activity in the region are major trends.

Some of the main competitors dominating the global Alzheimer’s drugs market include -- Abbvie Inc., AstraZeneca PLC, Biogen Inc., Daiichi Sankyo Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc and Teva Pharmaceutical Industries Limited

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • paypal
  • amazon
  • visa
  • master card

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed